FACULTY COMMENTS
DR LONIAL: This was an updated analysis of the APEX trial, and
we learned that the response rate with bortezomib increased.
This paper shows that with longer follow-up, the responses we
saw in APEX held up and were durable. This is further confirmation
of the data we had from the original paper.
The other piece of information I would take away from this paper is that patients on APEX were treated for a total of eight cycles, unless they achieved a CR, in which case they were treated for two cycles beyond CR. I believe the key is to treat them to maximal benefit, which in this trial was eight cycles.
DR ORLOWSKI: Richardson’s extended follow-up of the APEX
trial — comparing bortezomib versus high-dose dexamethasone
in patients with relapsed multiple myeloma — provides us with
longer follow-up. With a median follow-up of 22 months, we see
the response rate with bortezomib increases from the previously
reported 38 percent to 43 percent.
| Table of Contents | Top of Page |
